It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa ...
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the ...
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results